Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Aptorum Group Ltd (APM) USD1 A

Sell:$2.45 Buy:$2.70 Change: $0.05 (2.01%)
Market closed |  Prices as at close on 4 August 2021 | Switch to live prices |
Sell:$2.45
Buy:$2.70
Change: $0.05 (2.01%)
Market closed |  Prices as at close on 4 August 2021 | Switch to live prices |
Sell:$2.45
Buy:$2.70
Change: $0.05 (2.01%)
Market closed |  Prices as at close on 4 August 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Aptorum Group Limited is a pharmaceutical company dedicated to the discovery, development and commercializing of therapeutic assets to treat diseases, particularly infectious diseases and cancers (including orphan oncology indications). Through the establishment of drug discovery platforms, it enables the discovery of new therapeutics assets through systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. In addition to this, the Company is also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women’s health and other disease areas. It also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms.

Contact details

Address:
17 Hanover Square
LONDON
W1S 1BN
United Kingdom
Telephone:
+44 (20) 80929299
Website:
www.aptorumgroup.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
APM
ISIN:
KYG6096M1069
Market cap:
$85.19 million
Shares in issue:
34.02 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
Cayman Islands
Currency:
US dollar
Indices:
n/a

Key personnel

  • Darren Lui
    President, Executive Director
  • Ian Huen
    Chief Executive Officer, Founder, Executive Director
  • Sabrina Khan
    Chief Financial Officer
  • Angel Ng
    Chief Operating Officer
  • Clark Cheng
    Chief Medical Officer and Executive Director
  • Thomas Lee
    Head of Research and Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.